InnoCare Pharma Limited (9969.HK) is currently considered not halal (non-compliant), per In-house ratio engine (last assessed 2026-08-27). See the full ratio breakdown and business-activity screen below for the reasoning.
⚠️ Financial ratios are only half the screen. A company whose core business is in an excluded sector — weapons/defense, alcohol, gambling, conventional (interest-based) finance, tobacco, pork, or adult entertainment — is non-compliant even if every debt and income ratio passes. So passing ratios below don't override this verdict; check the business-activity screen for the reason.
Computed from Yahoo Finance fundamentals (Tier-4 provider, no filing available), balance sheet as of 2025-12-31. 9969.HK files no SEC reports, so these ratios come from the issuer's own published statements rather than XBRL.
Business activity: cleared (no excluded categories detected)
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 5.88% | 30.00% | Pass |
| Interest-bearing investments | 32.20% | 30.00% | Fail |
| Non-permissible income | 5.04% | 5.00% | Fail |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 12.34% | 33.00% | Pass |
| Interest-bearing investments | 67.59% | 33.00% | Fail |
| Non-liquid assets | 27.74% | at least 20.00% | Pass |
| Non-permissible income | 5.04% | 5.00% | Fail |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 12.34% | 33.33% | Pass |
| Cash + interest-bearing securities | 67.59% | 33.33% | Fail |
| Accounts receivable | 72.26% | 33.33% | Fail |
| Non-permissible income | 5.04% | 5.00% | Fail |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 12.34% | 33.33% | Pass |
| Cash + interest-bearing securities | 67.59% | 33.33% | Fail |
| Accounts receivable | 72.26% | 50.00% | Fail |
| Non-permissible income | 5.04% | 5.00% | Fail |
Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 6.85% | 33.00% | Pass |
| Cash + interest-bearing securities | 37.51% | 33.00% | Fail |
| Accounts receivable | 2.59% | 33.00% | Pass |
| Non-permissible income | 5.04% | 5.00% | Fail |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 8.32% | 33.00% | Pass |
| Cash + interest-bearing securities | 45.56% | 49.00% | Pass |
| Accounts receivable | 3.15% | 49.00% | Pass |
| Non-permissible income | 5.04% | 5.00% | Fail |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing debt | 8.32% | 33.33% | Pass |
| Cash + interest-bearing securities | 45.56% | 33.33% | Fail |
| Accounts receivable | 48.70% | 49.00% | Pass |
| Non-permissible income | 5.04% | 5.00% | Fail |
Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally above. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 41.80 | NEUTRAL |
| Stochastic %K (14) | 13.08 | BUY |
| CCI (20) | -215.54 | BUY |
| Williams %R (14) | -86.92 | BUY |
| MACD (12,26,9) | -0.14 | SELL |
| ROC (10) | -7.70 | SELL |
| Momentum (10) | -1.13 | SELL |
| EMA (10) | 14.31 | SELL |
| SMA (10) | 14.42 | SELL |
| EMA (20) | 14.37 | SELL |
| SMA (20) | 14.46 | SELL |
| EMA (30) | 14.29 | SELL |
| SMA (30) | 14.42 | SELL |
| EMA (50) | 14.02 | SELL |
| SMA (50) | 14.26 | SELL |
| EMA (100) | 13.66 | SELL |
| SMA (100) | 13.20 | BUY |
| EMA (200) | 13.79 | SELL |
| SMA (200) | 13.14 | BUY |
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Healthcare · Biotechnology
InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases in China. The company develops Orelabrutinib, an BTK inhibitor to treat patients with relapsed and/or refractory (r/r) chronic lymphocytic leukemia, r/r mantle cell lymphoma, r/r Waldenstrom's macroglobulinemia, r/r marginal zone lymphoma, r/r diffuse large B-cell lymphoma (DLBCL)- MCD, r/r central nervous system lymphoma, combo w/MIL-62, systemic lupus erythematosus, immune thrombocytopenia purpura, multiple sclerosis, and neuromyelitis optica spectrum disorder. It also developing ICP-B02 to treat CD20+B-cell malignancies; ICP-B05 to treat hemato-oncology; ICP-248 to treat chronic lymphocytic leukemia; ICP-332 to treat atopic dermatitis; ICP-488 to treat psoriasis; ICP-538 to treat autoimmune diseases; zurletrectinib (ICP-723) to treat neurotrophic tyrosine receptor kinase fusion positive cancers; ICP-189 to treat non-small cell lung cancer; and ICP-B05 to treat solid tumor. InnoCare Pharma Limited was incorporated in 2015 and is headquartered in Beijing, China.
Background via Yahoo Finance — informational, not part of the verdict.
Peer movement computing — it will appear here on its own.
NO DATA 0 buys · 0 sells
NEUTRAL report date 2026-09-08 · Asset managers net 912361 (-21819)
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.